

Programme Track 1: Prevention

Monday, September 16

17.00 Opening Plenary

18.30 Welcome Reception

Tuesday, September 17

07.00 Breakfast Seminar

08.00 Plenary

09.30 Break

10.00 – 12.30 Parallel Sessions

**Organised Session:
Neglected Disease R&D Through the Lens of a Public-Private Partnership Model**

Abstract Session:

503

A new rapid acting anti-wolbachia drug for onchocerciasis and lymphatic filariasis

Hong W.D., Johnston K.L., Berry N.G., Gusovsky F., Hemingway J., Turner J.D., Taylor M.J., Ward S.A., O'Neill P.M. (UK & USA)

578

The hidden hand of asymptomatic infection hinders control of neglected tropical diseases

Rock K.S., Chapman L.A.C., Dobson A., Adams E.R., Hollingsworth T.D. (UK & USA)

451

Are we there yet? Assessing who is being left behind and why in preventive chemotherapy treatment for neglected tropical diseases

Simpson S.J., Muleta M.D., Negussu N., Zeleke Z.K., Adekeye O., Shu'aibu J., Isiyaku S., Dean L., Koller T.S., Mbabazi P.S. (France, Ethiopia, Nigeria & Switzerland)

12.30 Lunch break – Sponsored Session / Poster Tour

14.00 Organised Session

Mucosal parasites-microbiota interactions in health and disease: a British Society for Parasitology perspective

15.30 Break

Programme Track 1: Prevention

16.00 – 18.30 Abstract Sessions

796

Using country-specific modelling of malaria interventions for national strategic planning

Runge M., Mohamed A., Mandike R., Molteni F., Thawer S., Lengeler C., Smith T., Pothin E. (Switzerland, Tanzania & USA)

577

Ipamu - a Madagascar-Germany partnership project aiming to investigate health care worker infections during the 2017 pneumonic plague outbreak

Kratz T., Andrianasolo R., Meurs L., Markus I.; Kolie D.; Rajerison M.; Rakoto Andrianarivelo M.; Malvy D.; Grunow R.; Razafimbiana V. (Germany, Madagascar, Sweden, Guinea & France)

132

A behavior change model for latrine construction and use in rural Côte d'Ivoire

Koffi A.V., Essé C., Kouassi D., Yapi B.R., Moro M.H., Kouakou C., Bonfoh B., N'Goran K.E., Utzinger J., Raso G. (Côte d'Ivoire & Switzerland)

900

District level malaria risk in mainland Tanzania: Developing a stratification approach for targeted malaria intervention strategies

Thawer S., Mohamed A., Chacky F., Runge M., Mandike R., Mkude S., Pothin E., Snow RW., Molteni F. (Tanzania, Switzerland, Kenya & UK)

147

Recurrence behaviour and relapse characteristics of Plasmodium ovale spp. in Gabon

Groger M., Veletzky L., Lalremruata A., Meyer E. L., Cattaneo C., Mischlinger J., Mombongoma G., Blessborn D., Führer H.-P., Ramharter M. (Germany, Gabon, Austria, UK & Thailand)

1100

Another way of mapping malaria transmission intensity in Nigeria and beyond

Nakakana U.N., Ahmed M.I., Jiya N.M., Jega R.M., Onankpa B.O. (Nigeria & Gambia)

337

One-health or eco-health initiatives for the control of vector-borne zoonotic diseases: Not an easy task in complex diseases such as human fascioliasis

Mas-Coma S., Bargues M.D. (Spain)

Programme Track 1: Prevention

Wednesday, September 18

07.00 Breakfast Seminar

08.00 Plenary

09.30 Break

10.00 – 12.30 Parallel Sessions

Organised Session:

Next Generation Nets, including:

839

Critical decision making and fighting insecticide resistance in malaria prevention

Sherratt P. (UK)

1164

Indoor Residual Spraying for Malaria control: Past, present anddoes it have a future?

Invest J., Lucas J. (UK)

Abstract Session:

707

Modelling the impact of pyrethroid resistance on the mass community effect of long-lasting insecticide treated nets

Unwin H.J.T., Sherrard Smith E., Churcher T.S., Ghani A.C. (UK)

575

The effects of insecticidal bed nets on insecticide resistant mosquito host seeking and blood feeding behaviour

Guy A., Foster G., Matope A., Parker J., Voloshin V., Ranson H., Towers D., McCall P.J. (UK)

111

Relationships between abundance of early instar larvae in aquatic habitats and oviposition in the malaria vector *Anopheles arabiensis* using genotypic reconstruction of sibling groups

Odero J.O., Fillinger U., Rippon E.J., Masiga D.K., Weetman D. (Kenya & UK)

12.30 Lunch break – Sponsored Session / Poster Tour

14.00 Parallel Sessions

Abstract Session:

857

Autodissemination of pyriproxyfen suppress a stable population of *Anopheles arabiensis* under semi-controlled settings

Programme Track 1: Prevention

Lwetoijera D., Kiware S., Okumu F., Devine G.J., Majambere S. (Tanzania, USA, UK, South Africa, Australia & Kenya)

210

High levels of copy number variation in metabolic insecticide resistance genes in malaria mosquitoes

Lucas E.R., Miles A., Harding N.J., Lawniczak M.K.N., Weetman D., Kwiatkowski D.P., Donnelly M.J.D., the Ag1000G consortium (UK)

830

Measuring the interaction of mosquitoes with biocide products using 3D infrared video tracking

Fatou M., Fry S.N., Müller P. (Switzerland)

339

Lymnaeid snail vector control within one-health or eco-health initiatives against human fascioliasis

Bargues M.D., Mas-Coma S. (Spain)

15.30 Break

16.00 – 18.30 Parallel Sessions

Abstract Session:

473

Costing of an integrated approach for Human African Trypanosomiasis (HAT) case finding in the Democratic Republic of the Congo

Snijders R., Fukinsia A., Mulenga P., Claeys Y., Hasker E., Mpanya A., Miaka E., Meheus F., Lutumba P., Boelaert M. (Belgium, DRC & France)

686

Tsetse control in g-HAT foci : For how long and how to stop?

Rayaisse J.B., Tirados I., Kaba D., Mahamat H.M., Kagbadouno M., Mugenyi A., Peka M., Courtin F., Camara M., Solano P. (Burkina Faso, UK, Côte d'Ivoire, Chad, Guinée, Uganda & France)

297

New advances in vector control against Human African Trypanosomiasis: the experience of 'Tiny Targets' to control Glossina fuscipes

Tirados I.¹, Selby R.¹, Hope A.¹, Rayaisse J.-B.², Vander Kelen C.³, Kovacic V.^{1,4}, Mansinsa P.⁵, Mahamat H.M.⁶, Mugenyi A.⁷, Solano P. (UK, Burkina Faso, Belgium, France, DRC, Chad & Uganda)

Organised Session:

Sleeping sickness elimination, challenges ahead in the Democratic Republic of the Congo

18.30 Conference Dinner

Programme Track 1: Prevention

Thursday, September 19

07.00 Breakfast Seminar

08.00 Plenary

09.30 Break

10.00 – 12.30 Parallel Sessions

Organised Session:

PfSPZ vaccines: Phase 3 to licensure to deployment and use in elimination campaigns.

Abstract Session:

230

Cost-effectiveness analysis of point-of-care (POC) assay lamp for human schistosomes

Brittany P., Chummy S.S., James M., Nilanjan L. (USA & Zambia)

478

Innovative tools for assessing infectiousness in asymptomatic carriers of *L.donovani*: A proof of concept study of a novel microbiopsy device

Cloots K., Singh O.P., Van der Auwera G., Hasker E., Singh A.K., Gedda M.R., Rai T., Malaviya P., Sundar S., Boelaert M. (Belgium & India)

769

Automated "sample to answer" diagnostic platforms (MalVec-LabDisk / ArboVec-LabDisk) for improving the impact of vector control interventions

Mavridis K., HinS., Mitsakakis K., Müller P., Wipf N., Medves S., Vontas J. (Greece, Germany, Switzerland & Germany)

12.30 Lunch break – Sponsored Session / Poster Tour

14.00 Organised Session:

Advances in diagnostics for Neglected Tropical Diseases

15.30 Break

16.00 – 18.30 Parallel Sessions

Abstract Session:

295

Feasibility and impact of leprosy post-exposure prophylaxis: Evidence from LPEP, a multi-country, 5-year implementation research program

Richardus J.H., Cavaliero A., Steinmann P., LPEP Study Group (The Netherlands & Switzerland)

Programme Track 1: Prevention

506

Mobile foot care unit – An innovative approach by LEPRA in Bihar, India

Singh R.K., Kumar S., Kumar D. (India)

145

Scabies a neglected tropical disease and health promotion in a boarding school in Sleman, Yogyakarta, Indonesia

Agustiningtyas I., Mulyaningrum U., Soleman S.R., Lusiantari R., Budiastuti E. (Indonesia)

142

Vertical transmission of Zika virus in *Culex quinquefasciatus* Say and *Aedes aegypti* (L.) mosquitoes

Phumee A., Chomposri J., Intayot P., Boonserm R., Boonyasuppayakorn S., Buathong R., Tawatsin A., Joyjinda Y., Wacharapluesadee S., Siriyasatien P. (Thailand)

143

Molecular epidemiology and genetic diversity of Zika virus from field-caught mosquitoes in various regions of Thailand

Phumee A., Buathong R., Boonserm R., Intayot P., Aungsananta N., Jittmittraphap A., Thavara U., Joyjinda Y., Wacharapluesadee S., Siriyasatien P. (Thailand)

963

Sentinel surveillance through travellers: Evaluation of an FTA card based mosquito saliva trap for arbovirus monitoring

Hedrich N., Vavassori L., Guedes R.D., Paiva M. H.S., Beuret C., Neumayr A., Müller P. (Switzerland & Brazil)

Programme Track 1: Prevention

Friday, September 20

08.00 – 10.00 Parallel Sessions

Abstract Session:

487

Increasing uncertainty on the dengue vaccine: A thematic analysis of the acute media coverage of the Philippine dengue vaccination

Valido E., Jumalon N.J., Roberto G. (Philippines)

827

Impact of concomitant administration of oral or injectable poliovirus vaccine on rotarix immunogenicity in South India

Parker E.P.K., Babji S., Sindhu K.N., Immanuel S., Kumar V., John A.J., Ganesan S.K., Praharaj I., Kang G., Iturriza-Gómara M., on behalf of the RoVI Consortium (UK & India)

112

Ex vivo evaluation of cellular immune responses elicited in human PBMC by live attenuated leishmania parasite vaccine candidate

Salotra P., Avishek K., Selvapandiyan A., Gannavaram S., Ramesh V., Nakhasi H.L. (India & USA)

398

In a setting with limited measles infection, can a measles vaccination campaign reduce all-cause minor morbidity? A study nested into a cluster randomized trial among children aged 9-59 months in rural Guinea-Bissau, West Africa

Varma A., Aaby P., Rodrigues A., Thysen S.M., Benn C.S., Jensen A.K.G., Fisker A.B. (Denmark & Guinea-Bissau)

1034

Empowering malaria research in Africa: Controlled human malaria infection in Tanzania, Kenya, Gabon, Mali, Equatorial Guinea and the Gambia to test the efficacy of malaria vaccines and drugs and to investigate innate resistance and acquired immunity to malaria

Richie T.L., for the International PfSPZ Consortium (USA)

10.00 **Break**

10.30 **Organised Session:**

New biomarkers for point-of-care malaria diagnostic tests

Organised Session:

Splicing the schemes: Quality assessment for molecular diagnostics of parasites

12.00 **Closing Plenary**